AAAAAA
Results: 26-39/39
Authors:
Beinert, T
Mergenthaler, HG
Sezer, O
Loffel, J
Binder, D
Oehm, C
Werner, T
Possinger, K
Citation: T. Beinert et al., Hypoxia in solid tumours, DEUT MED WO, 124(17), 1999, pp. 534-540
Authors:
Sezer, O
Jugovic, D
Blohmer, JU
Turzynski, A
Thiel, G
Langelotz, C
Possinger, K
Kovar, H
Citation: O. Sezer et al., CD99 positivity and EWS-FLI1 gene rearrangement identify a breast tumor ina 60-year-old patient with attributes of the Ewing family of neoplasms, DIAGN MOL P, 8(3), 1999, pp. 120-124
Authors:
Schmid, P
Akrivakis, K
Flath, B
Grosse, Y
Sezer, O
Mergenthaler, HG
Possinger, K
Citation: P. Schmid et al., Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer, ANTI-CANC D, 10(7), 1999, pp. 625-631
Authors:
Akrivakis, K
Schmid, P
Flath, B
Schweigert, M
Sezer, O
Mergenthaler, HG
Possinger, K
Citation: K. Akrivakis et al., Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study, ANTI-CANC D, 10(6), 1999, pp. 525-531
Authors:
Sezer, O
Schmid, P
Hallek, M
Schweigert, M
Beinert, T
Langelotz, C
Mergenthaler, HG
Possinger, K
Citation: O. Sezer et al., Eosinophilia during fludarabine treatment of chronic lymphocytic leukemia, ANN HEMATOL, 78(10), 1999, pp. 475-477
Authors:
Sezer, O
Schweigert, M
Naujokat, C
Mai, I
Mergenthaler, HG
Possinger, K
Citation: O. Sezer et al., In vitro and in vivo correlation of cyclosporin A-induced apoptosis in acute lymphoblastic leukemia, EUR J HAEMA, 63(3), 1999, pp. 207-209
Authors:
Sezer, O
Dabak, K
Anac, O
Akar, A
Citation: O. Sezer et al., Synthesis of triazolylbenzoisoxazole derivatives, HETEROCYC C, 5(1), 1999, pp. 83-88
Authors:
Sezer, O
Schmid, P
Mergenthaler, HG
Beinert, T
Possinger, K
Citation: O. Sezer et al., Use of bisphosphonates in therapy and prophylaxis of cancer-induced bone diseases, ONKOLOGIE, 22(5), 1999, pp. 400-404
Authors:
Beinert, T
Mergenthaler, HG
Sezer, O
Possinger, K
Citation: T. Beinert et al., Palliative chemotherapy in advanced non-small-cell lung cancer: Goals and reality, ONKOLOGIE, 22(1), 1999, pp. 63-64
Authors:
Sezer, O
Schmid, P
Schweigert, M
Heider, U
Eucker, J
Harder, H
Sinha, P
Radtke, H
Possinger, K
Citation: O. Sezer et al., Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cellsupport, BONE MAR TR, 23(9), 1999, pp. 967-969
Authors:
Luftner, D
Wagner, K
Dingeldein, G
Haas, A
Sezer, O
Mergenthaler, HG
Wernecke, KD
Possinger, K
Citation: D. Luftner et al., Adjuvant high-dose chemotherapy with epirubicin and ifosfamide in nodal positive breast cancer, ANTICANC R, 19(4C), 1999, pp. 3583-3590
Authors:
Icli, S
Astley, AS
Timur, C
Anac, O
Sezer, O
Dabak, K
Citation: S. Icli et al., Fluorescence emission studies on 1-phenyl-4-aroyl (and acyl)-1H-1,2,3-triazoles, J LUMINESC, 82(1), 1999, pp. 41-48
Authors:
Stead, ML
Brown, JM
Velikova, G
Kaasa, S
Wisloff, F
Child, JA
Hippe, E
Hjorth, M
Sezer, O
Selby, P
Citation: Ml. Stead et al., Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma, BR J HAEM, 104(3), 1999, pp. 605-611
Authors:
Naujokat, C
Sezer, O
Possinger, K
Citation: C. Naujokat et al., Tumor necrosis factor-alpha and interferon-gamma induce expression of functional Fas ligand on HT29 and MCF7 adenocarcinoma cells, BIOC BIOP R, 264(3), 1999, pp. 813-819